3 Months Pyrilutamide(1.5 Months 1% ) + Alfatradiol 0.1% + Minoxidil Treatment 11/15/2024
The conversation discusses using Pyrilutamide, Alfatradiol 0.1%, and Minoxidil for hair loss treatment. Pyrilutamide is described as a strong antiandrogen, and Alfatradiol is noted for its effectiveness in inhibiting DHT on the scalp.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity My theory is that combining pyrilutamide with alfatrodial could be similar in efficacy to finasteride.
Combining pyrilutamide and alfatradiol might be as effective as finasteride for hair maintenance. The user plans to try this combination alongside minoxidil and keto shampoo, hoping for improved hair thickness.
community Topical Anti-Androgen users. What are y’all using currently? And what do you believe has the best chance of being approved? Or best results?
RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.
community Almost 4 months, before and after of pyrilutamide .5% once daily
The user experienced significant hair regrowth using a combination of minoxidil, alfatradiol, pyrilutamide, and nizoral, despite previous intolerance to finasteride. They emphasize the importance of consistency in treatment and are optimistic about the results, noting no side effects so far.
community Combining oral dut with topical finasteride for reduced scalp DHT
The conversation discusses combining oral dutasteride with topical finasteride to further reduce scalp DHT levels for hair regrowth. Users debate the effectiveness and safety of this combination, with some suggesting alternatives like topical antiandrogens such as RU58841, fluridil, and alfatradiol.
community Guys, we finally have an alternative to finasteride
A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.
Related Research
6 / 6 resultsresearch Updates in Treatment for Androgenetic Alopecia
This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
research 587 Efficacy and Safety of topical KX-826 in Male Subjects with Androgenetic Alopecia:A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study
Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.
research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
research The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.